The splice-site variant represented a significantly higher proportion of all BRCA2 P/LPVs detected in MBC carriers compared to female breast cancer (FBC) carriers (47.4% vs. 26%, p = 0.049). This evidence concerns the gene BRCA2 and breast cancer.